Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of PF614 and Nafamostat in Healthy Subjects
NCT06500793Phase 1Recruiting
- Sponsor
- Ensysce Biosciences
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF614 and Nafabelltan in pain (2 arms), sponsored by Ensysce Biosciences. Primary endpoints: Time to Maximum Plasma Concentration at 72 hours, Maximum Plasma Concentration at 72 hours and 4 more. Started Nov 2024; status: recruiting.
02
Drugs
PF614Nafabelltan
03
Conditions
pain
Beyond the preview
Go deeper on NCT06500793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500793.